News | November 14, 2022
Biocon Biologics features on ASIA IP ELITE List 2022
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
This is the fifth consecutive year that a Biocon Group company has made it to the Asia lP ELITE list
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
The European Commission will review the CHMP recommendation and is expected to make a final decision soon.
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The core of “LANXESS Biosecurity Solutions” is a portfolio of scientifically formulated, highly effective and versatile biocidal products
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
Through the collaboration, Lonza will gain access to Singzyme’s enzymatic conjugation platform enabling the site-specific binding of payloads with peptidic linkers to proteins of interest
The company has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’
It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.
Subscribe To Our Newsletter & Stay Updated
